Skip to main content
SpringerLink
Log in

A Practical Approach to Connective Tissue Disease-Associated Lung Disease

  • Chapter
  • First Online:
Diffuse Lung Disease

Abstract

The goal of this chapter is to provide a practical approach to connective tissue disease (CTD)-associated lung disease by focusing on commonly encountered problems in the management of this complex and heterogeneous patient population. Several illustrative cases are incorporated into the text and interstitial lung disease is a major focus because it occurs across the spectrum of the CTDs, is potentially the most devastating of pulmonary manifestations, and often poses the most significant challenges to the practicing clinician.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung diseases in collagen vascular diseases. Eur Respir J Suppl. 2001;32:69s–80.

    PubMed  CAS  Google Scholar 

  2. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med. 2004;25(3):549–59, vii.

    Google Scholar 

  3. Wiedemann HP, Matthay RA. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med. 1989;10(4):677–722.

    PubMed  CAS  Google Scholar 

  4. Frankel SK, Brown KK. Collagen vascular diseases of the lung. Clin Pulm Med. 2006;13(1):25–36.

    Google Scholar 

  5. Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford). 2006; 45(10):1312–3.

    CAS  Google Scholar 

  6. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest. 2002; 122(5):1858–60.

    PubMed  Google Scholar 

  7. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006;33(6):1189–93.

    PubMed  Google Scholar 

  8. Ognenovski VM, Ojo TC, Fox DA. Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol. 2008; 35(11):2279–82.

    PubMed  Google Scholar 

  9. Zimmer C, Beiderlinden M, Peters J. Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin Rheumatol. 2006;25(3):430–2.

    PubMed  Google Scholar 

  10. Hirabayashi Y, Shimizu H, Kobayashi N, Kudo K. Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. Intern Med. 2006;45(10):689–91.

    PubMed  Google Scholar 

  11. Jenks KA, Stamp LK, O’Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34(11):2201–3.

    PubMed  CAS  Google Scholar 

  12. Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WA. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol. 2007; 34(9):1934–7.

    PubMed  Google Scholar 

  13. Ochi S, Harigai M, Mizoguchi F, Iwai H, Hagiyama H, Oka T, et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol. 2006;16(5):316–20.

    PubMed  Google Scholar 

  14. Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol. 2005;15(3):173–9.

    PubMed  Google Scholar 

  15. Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Otsuka T, et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(10):1265–8.

    Google Scholar 

  16. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol. 2005;32(6):1160–3.

    PubMed  Google Scholar 

  17. Wong SP, Chu CM, Kan CH, Tsui HS, Ng WL. Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy. J Clin Rheumatol. 2009;15(8):389–92.

    PubMed  CAS  Google Scholar 

  18. Camus P. Drug induced infiltrative lung diseases. 4th ed. Hamilton: BC Decker; 2003.

    Google Scholar 

  19. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15(2):373–81.

    PubMed  CAS  Google Scholar 

  20. Suda T, Sato A, Toyoshima M, Imokawa S, Yoshitomi A, Tamura R, et al. Weekly low-dose methotrexate therapy for sarcoidosis. Intern Med. 1994;33(7): 437–40.

    PubMed  CAS  Google Scholar 

  21. Heffner JE, Sahn SA. Salicylate-induced pulmonary edema. Clinical features and prognosis. Ann Intern Med. 1981;95(4):405–9.

    PubMed  CAS  Google Scholar 

  22. Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127(5):356–64.

    PubMed  CAS  Google Scholar 

  23. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997;40(10):1829–37.

    PubMed  CAS  Google Scholar 

  24. Lynch DA, Quantitative CT. of fibrotic interstitial lung disease. Chest. 2007;131(3):643–4.

    PubMed  Google Scholar 

  25. Lynch DA, Travis WD, Muller NL, Galvin JR, Hansell DM, Grenier PA, et al. Idiopathic interstitial pneumonias: CT features. Radiology. 2005;236(1): 10–21.

    PubMed  Google Scholar 

  26. Tanaka N, Newell JD, Brown KK, Cool CD, Lynch DA. Collagen vascular disease-related lung disease: high-resolution computed tomography findings based on the pathologic classification. J Comput Assist Tomogr. 2004;28(3):351–60.

    PubMed  Google Scholar 

  27. Hwang JH, Misumi S, Sahin H, Brown KK, Newell JD, Lynch DA. Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr. 2009;33(3): 410–5.

    PubMed  Google Scholar 

  28. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest. 1996;109(4): 933–8.

    PubMed  CAS  Google Scholar 

  29. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003;348(26):2690–1. discussion 2690-1.

    PubMed  Google Scholar 

  30. Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34(5):1151–4.

    PubMed  Google Scholar 

  31. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990;88(5):470–6.

    PubMed  CAS  Google Scholar 

  32. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008;177(1):91–8.

    PubMed  CAS  Google Scholar 

  33. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56(6):2005–12.

    PubMed  Google Scholar 

  34. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. 2009;33(4):882–96.

    PubMed  CAS  Google Scholar 

  35. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1): 199–203.

    PubMed  CAS  Google Scholar 

  36. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1999;160(3):899–905.

    PubMed  CAS  Google Scholar 

  37. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162(6):2213–7.

    PubMed  CAS  Google Scholar 

  38. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002; 165(12):1581–6.

    PubMed  Google Scholar 

  39. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705–11.

    PubMed  Google Scholar 

  40. Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008;134(3): 601–5.

    PubMed  Google Scholar 

  41. Fischer A. Interstitial lung disease: a rheumatologist’s perspective. J Clin Rheumatol. 2009;15(2): 95–9.

    PubMed  Google Scholar 

  42. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J. 2006;28(5):893–6.

    PubMed  CAS  Google Scholar 

  43. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med. 2009;103(8): 1152–8.

    PubMed  Google Scholar 

  44. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J. 2008;31(1): 11–20.

    PubMed  CAS  Google Scholar 

  45. Homma Y, Ohtsuka Y, Tanimura K, Kusaka H, Munakata M, Kawakami Y, et al. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration. 1995;62(5):248–51.

    PubMed  CAS  Google Scholar 

  46. Fischer A, Swigris JJ, du Bois RM, Lynch DA, Downey GP, Cosgrove GP, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103(11):1719–24.

    PubMed  Google Scholar 

  47. Fischer A, Swigris JJ, du Bois RM, Groshong SD, Cool CD, Sahin H, et al. Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest. 2009;136(4):1072–8.

    PubMed  Google Scholar 

  48. Fischer A, Meehan RT, Feghali-Bostwick CA, West SG, Brown KK. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest. 2006;130(4):976–81.

    PubMed  Google Scholar 

  49. Fukuoka J, Lesile KO. Practical pulmonary pathology. A diagnostic approach. 1st ed. Philadelphia, PA: Churchill-Livingstone; 2005.

    Google Scholar 

  50. Travis WD, Colby TV, Koss MN, Rosado-de-Christenson ML, Muller NL, King Jr TE. Non-neoplastic disorders of the lower respiratory tract. 1st ed. Washington, DC: American Registry of Pathology and the Armed Forces Institute of Pathology; 2002.

    Google Scholar 

  51. Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med. 2007;28(4):369–78.

    PubMed  Google Scholar 

  52. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009;136(1): 23–30.

    PubMed  Google Scholar 

  53. Fujita J, Ohtsuki Y, Yoshinouchi T, Yamadori I, Bandoh S, Tokuda M, et al. Idiopathic non-specific interstitial pneumonia: as an “autoimmune interstitial pneumonia”. Respir Med. 2005;99(2):234–40.

    PubMed  Google Scholar 

  54. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007;176(7):691–7.

    PubMed  Google Scholar 

  55. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999;17(5):615–20.

    PubMed  CAS  Google Scholar 

  56. Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009;28(8):915–21.

    PubMed  CAS  Google Scholar 

  57. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010;138(2):251–6.

    PubMed  Google Scholar 

  58. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35–42.

    PubMed  CAS  Google Scholar 

  59. Fischer A, Brown KK, Frankel SK. Treatment of connective tissue disease related interstitial lung disease. Clin Pulm Med. 2009;16(2):74–80.

    Google Scholar 

  60. Walker WC, Wright V. Diffuse interstitial pulmonary fibrosis and rheumatoid arthritis. Ann Rheum Dis. 1969;28(3):252–9.

    PubMed  CAS  Google Scholar 

  61. Holgate ST, Glass DN, Haslam P, Maini RN, Turner-Warwick M. Respiratory involvement in systemic lupus erythematosus. A clinical and immunological study. Clin Exp Immunol. 1976;24(3):385–95.

    PubMed  CAS  Google Scholar 

  62. Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA, Maltby JD, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984;63(2):92–107.

    CAS  Google Scholar 

  63. Steen VD, Medsger Jr TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41(9):1613–9.

    PubMed  CAS  Google Scholar 

  64. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener’s granulomatosis. Arthritis Rheum. 1994;37(6):919–24.

    PubMed  CAS  Google Scholar 

  65. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962–70.

    PubMed  CAS  Google Scholar 

  66. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66.

    PubMed  CAS  Google Scholar 

  67. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026–34.

    PubMed  CAS  Google Scholar 

  68. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993;20(5):838–44.

    PubMed  CAS  Google Scholar 

  69. Steen VD, Lanz Jr JK, Conte C, Owens GR, Medsger Jr TA. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994;37(9):1290–6.

    PubMed  CAS  Google Scholar 

  70. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000; 132(12):947–54.

    PubMed  CAS  Google Scholar 

  71. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009;136(5):1333–40.

    PubMed  CAS  Google Scholar 

  72. Furst DE, Clements, PJ. Immunosuppressives. In: Hochberg MC SA, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 3rd ed. Spain: Mosby; 2003. p. 439–48.

    Google Scholar 

  73. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156–62.

    PubMed  CAS  Google Scholar 

  74. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1): 30–6.

    PubMed  CAS  Google Scholar 

  75. Liossis SN, Bounas A, Andonopoulos AP. Mycophe­nolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005–8.

    CAS  Google Scholar 

  76. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150–5.

    PubMed  Google Scholar 

  77. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133(2):455–60.

    PubMed  CAS  Google Scholar 

  78. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984;311(24): 1528–33.

    PubMed  CAS  Google Scholar 

  79. Nicholls A, Snaith ML, Maini RN, Scott JT. Proceedings: controlled trial of azathioprine in rheumatoid vasculitis. Ann Rheum Dis. 1973;32(6): 589–91.

    PubMed  CAS  Google Scholar 

  80. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990;322(5): 281–5.

    PubMed  CAS  Google Scholar 

  81. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25(2):205–12.

    PubMed  CAS  Google Scholar 

  82. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol. 2004;23(4):306–9.

    PubMed  CAS  Google Scholar 

  83. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229–42.

    PubMed  CAS  Google Scholar 

  84. Stolk JN, Boerbooms AM, de Abreu RA, de Koning DG, van Beusekom HJ, Muller WH, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(10):1858–66.

    PubMed  CAS  Google Scholar 

  85. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford). 2004;43(1):13–8.

    CAS  Google Scholar 

  86. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combi­nation Study Group. N Engl J Med. 1995;333(3): 137–41.

    PubMed  CAS  Google Scholar 

  87. Wells G, Tugwell P. Cyclosporin A in rheumatoid arthritis: overview of efficacy. Br J Rheumatol. 1993;32 Suppl 1:51–6.

    PubMed  Google Scholar 

  88. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. 1993;36(1):75–83.

    PubMed  CAS  Google Scholar 

  89. BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc. 1988;20(3 Suppl 4):136–43.

    PubMed  CAS  Google Scholar 

  90. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353(9166):1762–3.

    PubMed  CAS  Google Scholar 

  91. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8):2439–46.

    PubMed  CAS  Google Scholar 

  92. Koopman WJ. Dawn of the era of biologics in the treatment of the rheumatic diseases. Arthritis Rheum. 2008;58(2 Suppl):S75–8.

    PubMed  Google Scholar 

  93. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother. 2004;5(3):581–94.

    PubMed  CAS  Google Scholar 

  94. Vassallo R, Matteson E, Thomas Jr CF. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest. 2002;122(3):1093–6.

    PubMed  Google Scholar 

  95. Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med. 2005;11(5):461–6.

    PubMed  Google Scholar 

  96. Gasper WJ, Sweet MP, Golden JA, Hoopes C, Leard LE, Kleinhenz ME, et al. Lung transplantation in patients with connective tissue disorders and esophageal dysmotility. Dis Esophagus. 2008;21(7): 650–5.

    PubMed  Google Scholar 

  97. Rosas V, Conte JV, Yang SC, Gaine SP, Borja M, Wigley FM, et al. Lung transplantation and systemic sclerosis. Ann Transplant. 2000;5(3):38–43.

    PubMed  CAS  Google Scholar 

  98. Shitrit D, Amital A, Peled N, Raviv Y, Medalion B, Saute M, et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant. 2009; 23(2):178–83.

    PubMed  Google Scholar 

  99. Massad MG, Powell CR, Kpodonu J, Tshibaka C, Hanhan Z, Snow NJ, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg. 2005;29(11):1510–5.

    PubMed  Google Scholar 

  100. Schachna L, Medsger Jr TA, Dauber JH, Wigley FM, Braunstein NA, White B, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006;54(12):3954–61.

    PubMed  Google Scholar 

  101. Brieva J. Cyclophosphamide-induced acute respiratory distress syndrome. Respirology. 2007;12(5): 769–73.

    PubMed  Google Scholar 

  102. Spector JI, Zimbler H. Cyclophosphamide pneumonitis. N Engl J Med. 1982;307(4):251.

    PubMed  CAS  Google Scholar 

  103. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1851–6.

    PubMed  CAS  Google Scholar 

  104. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc. 2007;82(3):342–50.

    PubMed  Google Scholar 

  105. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167(5):735–40.

    PubMed  Google Scholar 

  106. Steen V, Medsger Jr TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516–22.

    PubMed  Google Scholar 

  107. Steen VD. The lung in systemic sclerosis. J Clin Rheumatol. 2005;11(1):40–6.

    PubMed  Google Scholar 

  108. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60(6):1831–9.

    PubMed  Google Scholar 

  109. Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest. 2009;136(5):1211–9.

    PubMed  Google Scholar 

  110. Bull TM. Screening and therapy of pulmonary hypertension in systemic sclerosis. Curr Opin Rheumatol. 2007;19(6):598–603.

    PubMed  Google Scholar 

  111. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160(2):600–7.

    PubMed  CAS  Google Scholar 

  112. Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr Opin Pulm Med. 2003;9(5):426–30.

    PubMed  Google Scholar 

  113. Pipavath SJ, Lynch DA, Cool C, Brown KK, Newell JD. Radiologic and pathologic features of bronchiolitis. AJR Am J Roentgenol. 2005;185(2):354–63.

    PubMed  Google Scholar 

  114. Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008; 67(9):1222–8.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, National Jewish Health, Denver, CO, USA

    Aryeh Fischer MD

  2. National Heart & Lung Institute, Imperial College, London, UK

    Roland M. du Bois MA, MD, FRCP

Authors
  1. Aryeh Fischer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland M. du Bois MA, MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aryeh Fischer MD .

Editor information

Editors and Affiliations

  1. University of Cincinnati, College of Medicine, Department of Internal Medicine, Eden Ave, Cincinnati, 45267-0565, Ohio, USA

    Robert P. Baughman

  2. of Respiratory Medicine, Imperial College, Emeritus Professor, Grand Ave 14, London, N10 3BB, United Kingdom

    Roland M. du Bois

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Fischer, A., du Bois, R.M. (2012). A Practical Approach to Connective Tissue Disease-Associated Lung Disease. In: Baughman, R., du Bois, R. (eds) Diffuse Lung Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9771-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9771-5_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-9770-8

  • Online ISBN: 978-1-4419-9771-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation